Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGN-Cogni.Q PK Dose Trial in Prostate Cancer
NCT05375539Phase 1Completed
- Sponsor
- Penn State Health Milton S. Hershey Medical Center
- Start
- May 2023
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AGN-CognI.Q in prostate cancer (PCa), sponsored by Penn State Health Milton S. Hershey Medical Center. Primary endpoints: Cardiac Safety Via Electrocardiography (EKG) up to 5 weeks and Safety Blood Laboratory Tests up to 5 weeks. Started May 2023; status: completed.
02
Drugs
AGN-CognI.Q
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05375539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05375539.